Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Immix Biopharma

    MCap

    USD55m

    Last close

    USD1.97

    ▲ 0.32 (19.39%)

    EML Payments

    MCap

    AUD366m

    Last close

    AUD0.97

    ▲ 0.08 (9.04%)

    Datatec

    MCap

    ZAR10,379m

    Last close

    ZAR44.50

    ▲ 3.07 (7.41%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary

Consumer

Sparks

Dr Martens (LSE: DOCS) – H125 results in line with expectations
Published by Russell Pointon

H125 was a tough period for Dr Martens, with a constant currency revenue decline of 16% (versus guidance of a 20% decline) and an adjusted EBIT loss of £4.3m versus a profit of c £40m in H124. FY25 is viewed as a year of transition and guidance is unchanged, which includes US direct to consumer returning to growth in H225 and US wholesale revenue declining by double digits for the year. Management points to encouraging trading, with all thee regions positive, albeit the peak weeks of trading are ahead. It has also indicated that its cost savings plan will deliver savings of £25m, at the top end of prior expectations.

Next Sparks Commentary in this sector >

Latest

Industrials | Comment

Information Services Corporation (ISV: TSX) – Ticker change to ISC and new contract win

Consumer | Comment

Focusrite (LSE: TUNE) – FY24 results weak as already indicated but signs of stabilisation

TMT | Comment

essensys (LSE: ESYS) expects to return to EBITDA profitability in FY25

TMT | Comment

STV Group (LSE: STVG) on track despite tough advertising market

Consumer | Comment

Topps Tiles (LSE: TPT) – FY24 adjusted PBT marginally better than our prior estimate

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free